Clinical trials: Food Safety
COVID-19 (Coronavirus Disease 2019)
The Safety, Tolerability and Pharmacokinetics Study of RAY1216 in Healthy Adult Participants
This is double-blind,randomized, single and multiple dose trial to evaluate the pharmacokinetics(PK), safety, tolerability and drug-drug interaction of RAY1216, and the effect of food on RAY1216 Pharmacokinetics.
- Trial name
- NCT05829551
- Testing
- RAY1216 dose 1, RAY1216 dose 2, RAY1216 dose 3
- Where
- China
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Guangdong Raynovent Biotech Co., Ltd
Healthy
Single and Multiple Ascending Oral Dose Study of RX-10001 in Healthy Volunteers
This study is being conducted to determine the safety, tolerability, pharmacodynamics and pharmacokinetics of RX-10001.
- Trial name
- NCT00941018
- Testing
- RX-10001
- Where
- Netherlands
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Resolvyx Pharmaceuticals, Inc
Healthy Volunteers
Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP1617 in Healthy Adult Non-Asian and Japanese Subjects Including Assessment of a Food Effect
The purpose of this study is to evaluate the safety and tolerability of single ascending oral doses of ASP1617 in healthy adult non-Asian and Japanese male and female participants.
- Trial name
- NCT04077879
- Testing
- ASP1617
- Where
- United States
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Global Development, Inc.
Healthy Subjects
A First-in-human Phase 1 Study of CP1050
This is a Phase I, first-in-human, double-blind, single-centre, randomised, placebo-controlled, single and multiple oral dose study in healthy subjects conducted in 4 parts (Part 1; Single-ascending dose, Part 2; Food-effect…
- Trial name
- NCT03468413
- Where
- United Kingdom
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- Curadim Pharma Co., Ltd.
Healthy Volunteers
Food Effect Study of AG-221 in Healthy Male Subjects
AG-221 is a first-in-class drug targeted specifically to inhibit the IDH2 enzyme. Small molecule inhibition of the IDH enzyme represents a new, targeted approach to cancer treatment.
- Trial name
- NCT02218346
- Testing
- AG221
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Agios Pharmaceuticals, Inc.
Safety
Single Dose and Multiple Dose Escalation Trial of an Oral Formulation of MRX-4
A phase one study of the safety, tolerability, and pharmacokinetics of a new oxazolidinone antibiotic. Cohorts of healthy adults (female and male) will participate in: single dose escalation study of increasing doses of MRX-4…
- Trial name
- NCT03033342
- Testing
- Oral single doses of MRX-4, Oral multiple doses of MRX-4, MRX-4 co-administered with omeprazole
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- MicuRx
Healthy
A Study to Learn Safety and Blood Levels of PF-07817883 in Healthy People
The purpose of this clinical trial is to learn if the study medicine (called PF-07817883) is safe and how it goes in and out of the body in healthy people. PF-07817883 is for the potential treatment of COVID-19.
- Trial name
- NCT05580003
- Testing
- PF-07817883, Midazolam, Moxifloxacin
- Where
- 2 sites in United States, Belgium
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Pfizer
Renal Cell Carcinoma
A Post Marketing Surveillance As Required By Philippine Food And Drug Administration
This is a post marketing surveillance which determines the safety profile of the product to Filipinos. This is a FDA requirement for registration.
- Trial name
- NCT01781442
- Testing
- Temsirolimus
- Sponsor
- Pfizer
Celiac Disease, Celiac
A Study of the Safety, Efficacy and Tolerability of Nexvax-2 in Patients With Celiac Disease (CeD)
A randomized, double-blind, placebo-controlled clinical study in human leukocyte antigen (HLA)-DQ 2.5+ adults with celiac disease (CeD).
- Conditions
- Celiac Disease, Celiac, Intestinal Disease, Malabsorption Syndromes
- Trial name
- NCT03644069
- Testing
- Nexvax2
- Where
- 41 sites in United States, Australia and 1 more
- Volunteers
- 146 people
- Sponsor
- ImmusanT, Inc.
Inflammatory Bowel Disease
A Clinical Study of SPH7854 Granules in Healthy Subjects.
To evaluate the safety of SPH7854 in healthy subjects.
- Trial name
- NCT06483373
- Testing
- SPH7854
- Where
- China
- Volunteers
- 111 people, healthy volunteers welcome
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
Healthy, Pharmacokinetics of ASP7991
A Study to Assess the Safety, Pharmacological Effect and Plasma Concentration of ASP7991 After Single Oral Administration to Healthy Volunteers
This study is to assess the safety, tolerability, plasma concentration and pharmacodynamics of ASP7991 after single oral administration to healthy volunteers. In part-1, ASP7991 is administered in a dose escalation design.
- Trial name
- NCT01675518
- Testing
- ASP7991
- Where
- Japan
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Nonhematologic Malignancies, Lymphoma
Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma
This is an open-label, multicenter, sequential, 5-arm, phase 1 study of oral IXAZOMIB designed to assess drug-drug interaction with ketoconazole (Arm 1), the relative bioavailability of 2 capsule formulations of IXAZOMIB (Arm 2)…
- Trial name
- NCT01454076
- Testing
- Ixazomib 2.5 mg, Ixazomib 4 mg Capsule A, Ixazomib 4 mg Capsule B
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Congenital Adrenal Hyperplasia (CAH)
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of OMS1620
The goal of this study is to explore the safety, drug concentrations and effects on adrenal gland hormones after a single dose or multiple doses of OMS1620 in healthy participants.
- Trial name
- NCT07811089
- Testing
- OMS1620
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- OMass Therapeutics Australia Proprietary Ltd
Infection, Human Immunodeficiency Virus
Single Dose Escalation Study of GSK2838232 in Healthy Subjects
GSK2838232 is a novel human immune virus (HIV) maturation inhibitor being developed for the treatment of chronic HIV infection. This study is the first administration of GSK2838232 in humans to establish the initial safety…
- Trial name
- NCT01802918
- Testing
- GSK2838232, Ritonavir
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Safety and Tolerability in Healthy Volunteers
Safety and Tolerability Evaluation of BP-LT
This study evaluates the safety and tolerability of the food ingredient BP-LT when added to a daily diet. BP-LT is a stable protein ingredient being functional in the gastrointestinal tract and without systemic absorption.
- Trial name
- NCT07819695
- Testing
- BP-LT
- Where
- Bangladesh
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Bactolife A/S
Chronic Pancreatitis
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of CBT-248 in Healthy Adult Participants
This study will test CBT-248, an experimental medicine being developed for chronic pancreatitis. Chronic pancreatitis causes ongoing inflammation and damage to the pancreas, which can cause pain and problems with digestion and…
- Trial name
- NCT07905053
- Testing
- CBT-248, Fasted - Period 1, Fed - Period 2
- Where
- Australia
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Cibus Therapeutics, Inc.
Healthy Participants
Assessment of the Safety, Tolerability and Pharmacokinetics of AV078 in Healthy Volunteers
This Phase 1 study in healthy adult volunteers is planned to evaluate the safety, tolerability, and pharmacokinetics (PK) of AV078, a selective inhibitor of mammalian target of rapamycin complex 1 (mTORC1).
- Trial name
- NCT06205381
- Testing
- AV078, Itraconazole, Midazolam
- Where
- 2 sites in Australia
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Aeovian Pharmaceuticals, Inc.
Healthy
Single and Multiple Ascending Dose and Food Effect PK Study in Healthy Adult and Elderly Subjects
A three (3) part study to evaluate the safety, tolerability and PK of RDN-929
- Trial name
- NCT03668314
- Testing
- RDN-929, RDN-929 TBD dose
- Where
- Netherlands
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Alkermes, Inc.
High Risk Coronary Artery Disease
A Study to Estimate the Effect of AZD5718 on the Pharmacokinetics (What Does the Body Does to the Drug) of Rosuvastatin to Measure the Relative Bioavailability (the Extent to Which a Drug or Other Substance Becomes Available to the Body) of AZD5718 Oral Suspension vs AZD5718 Immediate Release Tablet
This study is a randomized, open-label, 5-period, 5-treatment, single-dose, single-center, crossover study to estimate the effect of AZD5718 on the pharmacokinetics (PK) of rosuvastatin, and to assess the relative bioavailability…
- Trial name
- NCT02963116
- Testing
- AZD5718 IR tablet, AZD5718 oral suspension, Rosuvastatin tablet
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG3067 in Healthy Subjects.
The study is a First-in-Human, Phase I, randomized, double-blind, placebo-controlled, single center study, evaluating single and multiple ascending oral doses of GLPG3067 and the combination of GLPG3067 and GLPG2222 and the…
- Trial name
- NCT03128606
- Testing
- GLPG3067 single dose, GLPG3067 multiple dose, GLPG3067 oral suspension
- Where
- Belgium
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Lakefront Biotherapeutics NV